Man Group
CPRX

Man Group’s Catalyst Pharmaceutical CPRX Stock Holding History

Man Group’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.86M Buy
250,000
+164,162
+191% +$4.84M 0.01% 905
2026
Q1 		$2.13M Sell
85,838
-102,946
-55% -$2.45M ﹤0.01% 1552
2025
Q4 		$4.41M Sell
188,784
-275,218
-59% -$6.13M 0.01% 1139
2025
Q3 		$9.14M Buy
464,002
+33,098
+8% +$681K 0.02% 838
2025
Q2 		$9.35M Buy
430,904
+135,162
+46% +$3.19M 0.02% 805
2025
Q1 		$7.17M Sell
295,742
-20,075
-6% -$452K 0.02% 862
2024
Q4 		$6.59M Buy
315,817
+61,123
+24% +$1.31M 0.02% 907
2024
Q3 		$5.06M Sell
254,694
-215,150
-46% -$3.99M 0.01% 1022
2024
Q2 		$7.28M Sell
469,844
-149,567
-24% -$2.33M 0.02% 844
2024
Q1 		$9.87M Sell
619,411
-24,805
-4% -$374K 0.02% 705
2023
Q4 		$10.8M Buy
+644,216
New +$8.81M 0.03% 602
2023
Q3 		– Sell
-835,008
Closed -$11.2M – 711
2023
Q2 		$11.2M Buy
+835,008
New +$12M 0.03% 584
2023
Q1 		– Sell
-889,532
Closed -$14.7M – 428
2022
Q4 		$16.5M Buy
889,532
+102,432
+13% +$1.58M 0.06% 398
2022
Q3 		$10.1M Buy
+787,100
New +$9.33M 0.05% 471
2022
Q2 		– Sell
-256,100
Closed -$1.88M – 1115
2022
Q1 		$2.12M Sell
256,100
-136,800
-35% -$967K 0.01% 1203
2021
Q4 		$2.66M Buy
392,900
+87,000
+28% +$572K 0.01% 1094
2021
Q3 		$1.62M Hold
305,900
– – 0.01% 1225
2021
Q2 		$1.76M Sell
305,900
-58,327
-16% -$301K 0.01% 1258
2021
Q1 		$1.68M Sell
364,227
-629,335
-63% -$2.5M 0.01% 1162
2020
Q4 		$3.32M Sell
993,562
-141,500
-12% -$475K 0.01% 994
2020
Q3 		$3.37M Buy
1,135,062
+85,327
+8% +$334K 0.01% 1003
2020
Q2 		$4.85M Buy
1,049,735
+941,435
+869% +$4.23M 0.02% 678
2020
Q1 		$417K Buy
108,300
+34,500
+47% +$142K ﹤0.01% 1322
2019
Q4 		$277K Buy
+73,800
New +$345K ﹤0.01% 1689

Other funds holding CPRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Man Group's CPRX Position: Q2 2026 in Review

Man Group increased its Catalyst Pharmaceutical (CPRX) stake by 191% in Q2 2026, buying an estimated $4.84M and bringing the position to 250,000 shares worth $7.86M. The position accounts for 0.01% of the portfolio, ranked #905.

Man Group first reported a position in CPRX in Q4 2019 and has held it in 24 quarters since. The position peaked at $16.5M in Q4 2022. 395 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

  • Man Group held 250,000 shares of Catalyst Pharmaceutical worth $7.86M as of Q2 2026.
  • Man Group bought 164,162 Catalyst Pharmaceutical shares in Q2 2026, an estimated $4.84M.
  • Catalyst Pharmaceutical made up 0.01% of Man Group's portfolio in Q2 2026, its #905 holding.
  • Man Group first reported a position in Catalyst Pharmaceutical in Q4 2019 and has held it in 24 quarters since.
  • Man Group's Catalyst Pharmaceutical position peaked at $16.5M in Q4 2022.
  • 395 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on Man Group's 13F filing for Q2 2026, filed 14 Aug 2026.